Last Updated

10 Mar 2020

ADJust Study - Antimalaria Dose Justification and Tolerability study of DHA-Piperaquine in the 5-24 Kg weight band in Malawi

Objectives

The overall objective of this project is to assess a higher dose of Dihydroartemisinin-piperaquine (DHA-PPQ) in young kids for safety, particularly cardiac safety.

Currently, the recommended dose range of DHA-PPQ is so narrow it does not allow an easy age-based dose regimen. This study aims to add valuable safety data and will likely contribute to the determination of safe dose regimens for MDA strategies. Findings from this DHA-PPQ dose-ranging study in children will be very informative for MDA campaigns and other strategies aiming to reduce malaria transmission using this drug.

Date

2014 Jan - 2015 Sep

Total Project Funding

$620,352
Project Site